Edition:
United Kingdom

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.85USD
20 Apr 2018
Change (% chg)

$0.10 (+2.11%)
Prev Close
$4.75
Open
$4.72
Day's High
$4.95
Day's Low
$4.72
Volume
17,684
Avg. Vol
4,234
52-wk High
$6.50
52-wk Low
$3.13

Chart for

About

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a... (more)

Overall

Beta: --
Market Cap(Mil.): $33.47
Shares Outstanding(Mil.): 6.94
Dividend: --
Yield (%): --

Financials

  NVUS.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -7.20 -- --
ROI: -67.10 14.84 14.38
ROE: -67.53 16.34 16.07

BRIEF-Novus Therapeutics Reports Q4 Loss Per Share $0.30

* Q4 LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

02 Apr 2018

BRIEF-Novus Therapeutics Qtrly Loss Per Share $0.30

* QTRLY LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Andrew I. Mcdonald Reports 12.24 pct Passive Stake In Novus Therapeutics As Of March 9

* ANDREW I. MCDONALD REPORTS 12.24 PERCENT PASSIVE STAKE IN NOVUS THERAPEUTICS INC AS OF MARCH 9, 2018 - SEC FILING‍​ Source text - http://bit.ly/2FRbXVN Further company coverage:

13 Mar 2018

BRIEF-Novus Therapeutics Inc reported Q3 $0.43 loss per share​

* Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​ Source text: (http://bit.ly/2hldAkp) Further company coverage:

08 Nov 2017

BRIEF-Novus Therapeutics reports third quarter 2017 results

* Q3 loss per share $0.43 Source text for Eikon: Further company coverage:

08 Nov 2017

Earnings vs. Estimates